Intellia Therapeutics Inc (NTLA)

47.74
+0.03(+0.06%)
After Hours
47.50
-0.24(-0.50%)
- Real-time Data
  • Volume:
    1,136,518
  • Day's Range:
    43.49 - 50.20
  • 52 wk Range:
    38.85 - 202.45

NTLA Overview

Prev. Close
47.71
Day's Range
43.49-50.2
Revenue
37.85M
Open
48.76
52 wk Range
38.85-202.45
EPS
-5.04
Volume
1,136,518
Market Cap
3.62B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,189,966
P/E Ratio
-
Beta
2.11
1-Year Change
-25.5%
Shares Outstanding
75,853,870
Next Earnings Date
Aug 04, 2022
What is your sentiment on Intellia Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Intellia Therapeutics Inc News

Intellia Therapeutics Inc Analysis

Intellia Therapeutics Inc Company Profile

Intellia Therapeutics Inc Company Profile

Employees
485

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuySellSell
Technical IndicatorsStrong BuyStrong BuyBuySellStrong Sell
SummaryStrong BuyStrong BuyStrong BuySellStrong Sell
  • then sold
    2
    • kathy wood must have bought
      0
      • Will recover to 156! Mark my words as of Oct 9th!
        1
        • nice try, it's slowly moving up tho
          1
      • Miss on earnings and revenue but get a $33 peak bump in share price. what did I miss?
        0
        • results of thier studies
          0
      • time to buy a few and hold me thinks
        0
        • Any thought about this stock?
          0
          • waiting to get back in
            0
            • Feels too aggressive
              0
              • GLOP and CEPU, this are the next homeruns
                0
                • Buy????
                  0